We have a new anti-cancer peptide, PNC-27. We identified its cellular target and found that ketone bodies (KBs) enhance the inhibitory effect of PNC-27. Our data support the use of this system as a diagnostic method for cancer and we have preliminary evidence for its use in cervical cancer. The project will refine the system and anticipate its use in clinical diagnosis in order to overcome limitations of current methods.